End-of-day quote
Taiwan S.E.
06:00:00 2024-07-04 pm EDT
5-day change
1st Jan Change
306.5
TWD
+0.99%
-0.97%
+12.68%
Lotus Pharmaceutical Co., Ltd. Announces Election of Hirofumi Imai as Director, Effective from June 26, 2019
June 24, 2019 at 03:07 am EDT
Lotus Pharmaceutical Co., Ltd. announced election of Hirofumi Imai as director, effective from June 26, 2019.
Nrx Pharmaceuticals, Inc. Receives A Notice of Termination of Exclusive, Global ? Development, Supply, Marketing & License Agreement by and Between Alvogen, Inc., Alvogen Pharma Us, Inc. and Lotus Pharmaceutical Co. Ltd
Jun. 27
CI
Lotus Pharmaceutical Co., Ltd. Announces Audit and Remuneration Committee Changes
Jun. 13
CI
Lotus Pharmaceutical Co., Ltd. Announces Board Changes
Jun. 13
CI
Lotus International Pte. Ltd and Lotus Pharmaceutical Co., Ltd. agreed to acquire Teva Pharma Co., Ltd. from Actavis Group PTC ehf., Actavis Holding Asia BV and Actavis Dutch Holding B.V. for TWD 1.5 billion.
Jun. 05
CI
Transcript : Lotus Pharmaceutical Co., Ltd., Q1 2024 Earnings Call, May 16, 2024
May. 16
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 10
CI
Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director
Mar. 26
CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 13
CI
Lotus Pharmaceutical Co., Ltd. Announces the Appointment of Valerie Lau as APAC Chief Commercial Officer, Effective February 15, 2024
Jan. 31
CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Jan. 14
CI
Transcript : Lotus Pharmaceutical Co., Ltd., Q3 2023 Earnings Call, Nov 14, 2023
Nov. 14
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 09
CI
Alvogen Korea Holdings Ltd. announced that it expects to receive KRW 29.51962949 billion in funding from Lotus Pharmaceutical Co., Ltd.
23-09-24
CI
Lotus Pharmaceutical Co., Ltd. Announces Director Changes
23-09-04
CI
Lotus Pharmaceutical Co., Ltd. and Fuji Pharma Co., Ltd. Joint Product Receives the Approval for Lenalidomide Capsules,2.5 Mg and 5 Mg from the Japan Pmda
23-08-15
CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-10
CI
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
23-07-31
CI
PharmaMar Secures Taiwan Regulatory Approval for Lung Cancer Treatment
23-07-11
MT
Lotus Pharmaceutical Co., Ltd. Appoints Susan Liao as Acting Spokesperson
23-07-10
CI
Lotus Pharmaceutical Co., Ltd. Announces Appointment of the Remuneration Committee Members
23-07-10
CI
Lotus Pharmaceutical Announces Cash Distribution Payable on August 1, 2023
23-06-16
CI
Lotus Pharmaceutical Co., Ltd. Announces Board Changes
23-06-15
CI
Lotus Pharmaceutical Co., Ltd. Announces Tenure Expiration of the Remuneration Committee Members
23-06-14
CI
Lotus Pharmaceutical Co., Ltd. Announces Change in Audit Committee Members
23-06-14
CI
Lotus Pharmaceutical Co., Ltd. Announces Change of Directors
23-06-14
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Lotus Pharmaceutical Co Ltd is a Taiwan-based company mainly engaged in the manufacture and sale of generic drugs. The products are mainly solid preparations such as tablets and capsules. The main products include oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs and mental disease drugs. The Company is also engaged in the drug research, development and clinical testing business, as well as the product licensing business. The Company mainly distributes products in Taiwan, South Korea, the United States, China mainland, Japan, Europe and Southeast Asia markets.
More about the company
Last Close Price
306.5
TWD
Average target price
393.2
TWD
Spread / Average Target
+28.29%
Consensus
1st Jan change
Capi.
+12.68% 2.48B +56.89% 809B +39.52% 624B -6.55% 351B +7.92% 289B +13.74% 240B +13.83% 220B -0.49% 219B +7.94% 166B -2.57% 157B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1